Parasitic protozoa of the genus Leishmania cause a wide spectrum of human cutaneous, mucocutaneous, and visceral diseases that are major public health problems (6, 38) . Vaccination with living organisms that produce a lesion has been practiced for centuries in the Middle East and has been the basis for vaccination programs against the cutaneous forms of leishmaniasis in Israel and countries of the former USSR. However, complications that occur with the live vaccine (13) indicate the need for an attenuated or defined vaccine for cutaneous leishmaniasis. Immunization with purified leishmanial antigenic components has resulted in significant protection against infection in a murine model system (16, 23, 43, 45) . Our laboratory has investigated the ability of GP46/M-2, a promastigote surface membrane glycoprotein (32, 33) , to elicit a protective immune response; this molecule, when administered with an adjuvant, can elicit a protective response against infection in susceptible mice (5) . In addition, recently published observations indicate that the GP46/M-2 glycoprotein appears to be recognized by the T cells of infected individuals (3) . Although the GP46/M-2 protein was originally described for members of the Leishmania mexicana complex (14, 26) , recent evidence indicates that this protein is expressed in all major lineages of the genus (34) , except apparently the Leishmania braziliensis complex; consequently, GP46/M-2 may be useful in the development of a general vaccine against infection by this genus of parasitic protozoa. As effective immunization with purified GP46/M-2 may require continuous boosters in the presence of an adjuvant, a delivery system that can provide long-term immunological effects is needed. It has been well established that recombinants of vaccinia virus expressing many different genes can provoke long-term immunological effects at the T-and B-cell level that lead, in experimental animal model systems, to protection against challenge with a pathogen (1, 35) . Thus, it was of interest to determine whether the GP46/M-2 protein would elicit a protective response with a recombinant vaccine delivery system, potentially suitable for a human vaccine.
The present study used two distinct GP46/M-2-vaccinia virus recombinant vaccines, one derived from the wild-type (Wt) virus and the other derived from a highly attenuated variant, to induce protection against an infection with Leishmania amazonensis in the highly susceptible BALB/c strain of mice.
MATERIALS AND METHODS Parasite stocks and culture. L. amazonensis LTBOO16 (MHOM/BR/77/LTB0016) was used throughout this study. Organisms were cultured with Schneider's Drosophila medium containing 10% heat-inactivated fetal bovine serum (GIBCO) by methods previously described (18) and cloned into the SmnaI site of vaccinia virus insertion vector pSC11 (4) . As a result of this cloning strategy, plasmid pSCLEISH containing the GP46/M-2 coding sequence under the control of early-late vaccinia virus promoter p7.5 and 3-galactosidase under the control of late vaccinia virus promoter pll was isolated. pSCLEISH plasmid DNA was introduced into the thymidine kinase (TK) region of the Wt vaccinia virus or the attenuated variant 48-7 (8, 11, 40) genome by homologous recombination to generate WRLEISH and MuLEISH, respectively. 1-Galactosidaseproducing plaques were picked, cloned three times, and amplified in African green monkey kidney (BSC-40) cells.
Gel electrophoresis. Polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate (SDS-PAGE), unless otherwise indicated, was performed with 10% polyacrylamide under standard conditions (25) .
Radioimmunoprecipitations Additional groups of mice receiving the GP46/M-2-recombinant vaccinia viruses were further immunized 3 weeks later with 2 ,ug of purified native GP46/M-2 together with 50 p,g of Corynebacterium parvum (Wellcome Research Laboratories, Research Triangle Park, N.C.) or with C. parvum alone as previously described (5) . The mice were then challenged in the right hind foot with either 104 or 103 late-log-phase promastigotes of L. amazonensis 11 weeks after the initial immunization with the recombinant vaccinia viruses. A minimum of five mice were included in each vaccination group.
In the second experiment, BALB/c mice were immunized and boosted once with recombinant vaccinia viruses MuLEISH and WRLEISH as detailed above; mice did not receive a further immunization booster with purified native GP46/M-2. Nine weeks after the initial immunization with the recombinant vaccinia viruses, immunized animals (MuLEISH and WRLEISH; 24 mice in each group) and nonimmunized control animals (30 mice) were challenged with 10' late-log-phase promastigotes. Lesion development was monitored as an averaged ratio of the size of the infected right foot to that of the uninfected left foot with a micrometer (B. C. Ames Co., Waltham, Mass.) as previously described (5) . Approximately 8 months postinfection, apparently protectively immunized mice were examined for parasite burden at the site of inoculation by the limiting dilution method as previously described (5, 20, 47) . In addition, residual homogenized tissue was placed on blood agar slants and monitored for parasites.
Proliferative responses of BALB/c mice protectively immunized with VVRLEISH and MuLEISH. Spleen and lymph node cells were excised from immunized mice approximately 8 months postinfection, nearly 10 months after the final immunization with GP46/M-2-recombinant vaccinia virus WRLEISH or MuLEISH. Normal spleen and lymph node cells from nonimmunized BALB/c mice were used as controls. Cells (4 x 105/ml) were cultured in RPMI 1640 medium supplemented with 0.5% pooled mouse serum, gentamicin (50 pL/ml), glutamine (4 mM), and 2-mercaptoethanol (5 x 10' M) for 3 days in the presence or absence of antigen, as indicated; the cells were then pulsed with 1 p,Ci of [3Hlthymidine for 18 h and harvested onto glass microfiber filters for liquid scintillation counting (LKB 1209 RACKBETA). Promastigotes of L. amazonensis used as the test antigen were frozen-thawed through at least five cycles and stored at -70°C until used. GP46/M-2 was isolated as previously described by immunoaffinity chromatography (5, 22, 34) with modifications to ensure the removal of excess lipid (27) .
Cytokine assays. Spleen cells collected from immunized mice 11 months after parasite challenge were stimulated with 106 frozen-thawed promastigotes of L. amazonensis; culture supernatants were harvested and assayed for various cytokines. Interleukin-2 (IL-2) and IL-4 activities were deter- (26) (Fig. 1A) . Attenuated variant 48-7 contains several genetic lesions, including a large DNA deletion and a point mutation in the 14-kDa membrane protein (40) . After (Fig. 1C) . Thus, in cells infected with WRLEISH and MuLEISH, both the glycosylated and the nonglycosylated forms of GP46/M-2 are produced.
Indirect immunofluorescence experiments with rabbit anti-GP46/M-2 polyclonal serum and nonpermeable infected cells (Fig. 2) (Fig. 3 and Table 1 ).
BALB/c mice immunized with the GP46IM-2-recombinant vaccinia viruses alone and challenged with 103 L. amazonensis promastigotes showed a significant delay in the apparent onset of infection (Fig. 3) mastigotes, two of the protectively immunized mice were sacrificed, the sites of inoculation were excised, and the parasite burden was determined (20, 47) by the limiting dilution titration method; in addition, half of each homogenized excised tissue sample was placed on a blood agar slant for culturing. No L. amazonensis organisms were detected in either the titrated (diluted) or the undiluted tissue homogenate, although significant growth was observed for control parasites cloned at the same time. The remainder of the protectively immunized mice were maintained for over 1 year postinfection without any apparent signs of infection. These data indicate that these animals were completely protected against infection and that no inapparent or nonpathogenic infection occurred as a result of the vaccinia virus immunizations.
Mice that were immunized with either GP46/M-2-recombinant vaccinia virus and that received 104 L. amazonensis promastigotes showed a delay in both the onset and the course of infection (Fig. 3) . BALB/c mice that received the additional immunization with native GP46/M-2 and C. parvum showed no significant increase in their resistance to infection over those that received the recombinant vaccinia viruses alone (data not shown). In contrast, mice that received Wt vaccinia virus showed a slight exacerbation in the course of infection in comparison with nonimmunized control mice. The exacerbation observed was similar to that reported in a recent recombinant Salmonella typhimurium gp63 vaccine study, in which control mice receiving nonrecombinant S. typhimunium showed an exacerbation of infection in comparison with nonimmunized control mice (49) . The cause of such exacerbation is at present unclear.
These results were confirmed in a second experiment with both GP46/M-2-recombinant vaccinia virus vectors; 30 BALB/c mice in a control group and 24 experimental groups were challenged with 103 L. amazonensis promastigotes. Forty-five percent of the mice receiving either WRLEISH or MuLEISH showed no apparent signs of lesion development or infection. At approximately 8 months postinfection, four of the protectively immunized mice were examined for parasites as described above by the limiting dilution method of determining parasite burden (47) ; the animals were determined to be completely free of infection with L. amazonensis. Hence, these animals, as in the previous experiment, appeared to be completely protected against an infection with L. amazonensis. Immunized mice maintained for as long as 14 months postinfection remained free of any signs of infection.
Evaluation of the antibody responses of GP46/M-2-recombinant vaccinia virus-immunized mice. Sera from each group of mice were examined by Western blot analyses for antibodies to GP46/M-2, ,-galactosidase and vaccinia virus (Fig.   4) Examination of the T-cell responses of immunized mice. In the second experiment, the T-cell responses of the protectively immunized animals were also determined to evaluate the persistence of memory; these experiments were conducted approximately 10 months after the infective challenge, at which point it was clear that the animals had been protectively immunized. Antigen-specific proliferative responses were evident in lymphocytes from GP46/M-2-re- For further evaluation of the persistence of memory, the levels of murine IL-2, IL-4, IFN--y, and LT/TNF produced in response to L. amazonensis promastigotes were determined for cells obtained from protectively immunized animals (Table 3) . Cytokines were not detectable in supernatants of lymphocytes obtained from immunized animals and cultured in the absence of an antigen or lymphocytes obtained from normal animals and cultured in the presence of 106 L. amazonensis promastigotes per ml. However, when spleen cells from protectively immunized mice were cultured in the presence of an antigen, the supernatants contained activities for all the cytokines tested. These data, although indicating a low level of cytokine production in the presence of a specific antigen, clearly indicate that T cells, after a response to an antigen, produce measurable levels of all the cytokines examined. The rather low levels of cytokines produced are undoubtedly a function of the time postimmunization. The level of protection against infection at this time postimmunization is unclear; however, in terms of a potential vaccine for leishmaniasis, these data and the proliferation data Downloaded from a protective immunity study with an oral S. typhimurium gp63 recombinant vaccine resulted in lesions significantly smaller than those in control mice (49) . Both antibody and T-cell proliferative responses as well as a singular IL-2 and IFN--y Thl-type response were demonstrated in protectively immunized resistant CBA mice. Another study with a recombinant Escherichia coli gp63 vaccine (15) failed to demonstrate protection against infection with L. major; although evidence indicated that the antibody did not react with the native protein, T-cell responses were not evaluated. Hence, it is still unclear whether a lack of a specific T-cell response is responsible for the lack of protection observed in the previous study (15) . More recent investigations, however, have demonstrated that a specific synthetic T-cell epitope of gp63 is capable of eliciting a protective Thl immune response in mice (21) . In addition, CD8+ cells have been implicated in the control of a leishmanial infection in naive mice infected with Leishmania donovani as well as in studies of immunized and CD4+-depleted mice infected with L. major (9, 19, 29, 46) . Because of the established ability of vaccinia virus recombinants to stimulate CD8+ cytotoxic T-lymphocyte responses (2, 24, 30) , it is possible that these cells participate in the protection observed in the studies presented here. Although responses that could be mediated by CD4+ Thl and Th2 have been indicated in the current study, the relative contributions of CD4+ (Thl and Th2) and CD8+ T-lymphocyte subsets to the control of infection in these recombinant vaccinia virus-immunized mice remains to be determined and will be of interest in future studies with this model.
In conclusion, the potential to clone multiple genes encoding several distinct antigens within a single recombinant vaccinia virus and the existence of immunologically effective attenuated vaccinia virus strains are desirable in consideration of the development of a vaccine against a complex parasitic organism. These studies indicate that immunization with Leishmania-vaccinia virus recombinants can elicit the appropriate immunological response, resulting in protection against infection. Immunological memory for GP46/M-2 in the recombinant vaccinia virus-immunized animals appears to persist for a period of up to 1 year postimmunization. Both mutant attenuated and Wt vaccinia virus GP46/M-2 recombinants appear to be equally effective in eliciting a protective response. These studies clearly demonstrate that vaccinia virus recombinants may provide the basis for a safe and effective vaccine against leishmaniasis.
